Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates » October 2018 BCBS Tennessee Medical Policy Updates: Abatacept Applied Behavioral Analysis (ABA) Bortezomib Bortezomib (Velcade )…
Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates » September 2018 BCBS Tennessee Medical Policy Updates: Abatacept AbobotulinumtoxinA Agalsidase Beta Alemtuzumab Alglucosidase Alfa Angioplasty and/or…
Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates » August 2018 BCBS Tennessee Medical Policy Updates: Abatacept Abatacept Ablation Procedure for Peripheral Neuromas AbobotulinumtoxinA Bariatric…
Click here to view the Blue Cross Blue Shield Tennessee Draft Medical Policies » August 2018 BCBS Tennessee Draft Medical Policies: Abatacept Positron Emission Tomography (PET) for Cardiac Applications Acupuncture…
Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates » July 2018 BCBS Tennessee Medical Policy Updates: Abatacept Angioplasty and/or Stenting for Intracranial Arterial Disease (IAD)…
Click here to view the Blue Cross Blue Shield Tennessee Draft Medical Policies » July 2018 BCBS Tennessee Draft Medical Policies: Coronary Computed Tomography Angiograchy (CCTA) Three-Dimensional (3D) Printed Orthopedic…
Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates » June 2018 Medical Policy Updates: BRCA1, BRCA2 and PALB2 Testing for Breast, Ovarian and Other Cancers…
Click here to view the Blue Cross Blue Shield Tennessee Draft Medical Policies » June 2018 Draft Medical Policies: Ipilimumab Belinostat Non-invasive Positive Pressure Ventilators (In-Home Use) Sargramostim Nivolumab Ramucirumab…
Click here to view the Blue Cross Blue Shield Tennessee Draft Medical Policies » May 2018 Draft Medical Policies: Burosumab-twza Romidepsin Blinatumomab Olaratumab Temozolomide Reduction Mammoplasty (Non-Cancerous) Ixabepilone Temsirolimus Ramucirumab…
Click here to view the Blue Cross Blue Shield Tennessee Draft Medical Policies » April 2018 Draft Medical Policies: Tildrakizumab-asmn Pertuzumab Sildenafil Voretigene Neparvovec-rzyl Treprostinil for Continuous Subcutaneous Intravenous Infusion…